JPRN-UMIN000007397已完成2 期
A phase II study of Erlotinib plus Pemetrexed for previously treated Non Small Cell Lung Cancer - A phase II study of Erlotinib plus Pemetrexed for previously treated NSCLC
Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine0 个研究点目标入组 27 人开始时间: 2012年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2) Patients who have previously treated with EGFR-TKI and / or pemetrexed 3) Patients with active severe infections 4) Impossible cases with oral administration 5) Patients with active opthalmological disease 6) Pregnancy or lactation 7) Patients with symptomatic brain metastasis 8) Patients with active concomitant malignancy 9) Patients with uncontrollable complications (e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea) 10) Inappropriate patients for this study judged by the physicians
研究者
相似试验
招募中
2 期
A phase II study of Erlotinib plus Pemetrexed for Non Small Cell Lung Cancer with T790M negative previously treated with EGFR-TKIon-small cell lung cancerJPRN-UMIN000008033Toho University Omori Medical Center15
已完成
1 期
A Phase I/II study of Pemetrexed plus Erlotinib therapy in Previously Treated Non-Small-Cell Lung Cancer.on-small cell lung cancerJPRN-UMIN000002900Osaka Univ.Hospital Respiratory Medicine40
进行中（未招募）
1 期
A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2007-003912-72-GBEli Lilly and Company Limited237
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54